DiaSorin SpA
Alessandro Pellarin has a diverse work experience spanning across multiple companies and roles. Alessandro began their career at Laboratoires 3M Santé in 2002, where they worked as a Business Analyst Domestic for five years. In 2007, they joined 3M France as a Scotch Brite Manufacturing Analyst before moving to SPX France in 2008, where they served as a Financial Controller for two years. In 2010, Alessandro joined Manutan international as a Group Controller for Marketing & Purchasing, and they stayed with the company until 2012. From 2012 to 2017, they worked at DiaSorin as a Regional Financial Controller for Europe & Israel. Alessandro then transitioned to the role of Regional Financial Controller for North America at DiaSorin from 2017 to 2022. Most recently, Alessandro has taken up the position of Commercial Finance Director for North America at DiaSorin in 2022, and they currently hold the position of Commercial Finance Senior Director for Immuno and Molecular North America since 2023.
Alessandro Pellarin's education history includes a Leadership degree from SDA Bocconi in 2015. Alessandro also holds a Master II (ex DESS) in finance d'enteprise (en alternance) from UNIVERSITE EVRY VAL D'ESSONNE, which they obtained from 2000 to 2001. Prior to that, they earned a Master I (ex MSG) in finance (en alternance) from the same university from 1998 to 2000. Alessandro's education began with a DUT Techniques de Commercialisation (en alternance) from IUT CERGY PONTOISE, completed from 1996 to 1998. Alessandro attained their Baccalauréat scientifique from LYCEE INTERNATIONAL ST GERMAIN EN LAYE in 1996. In addition to their formal education, Alessandro has obtained certifications in Difficult Conversations: Talking about Race at Work, Inclusive Mindset for Committed Allies, and Unconscious Bias from LinkedIn in 2021.
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.